Skip to main content
Blizard Institute - Faculty of Medicine and Dentistry
  1. Blizard Institute
  2. Staff news and announcements
  3. Items

Funding Call - Proof of concept funding for autoimmune and chronic inflammatory therapeutics - Round 1

If you are developing a therapeutic technology that can change outcomes for patients with autoimmune and chronic inflammatory diseases, this might be for you.

Published:

Programme

  • Receive up to £50,000 to be used either internally or at a contract research organisation to generate early proof of concept data.
  • Co-development support for future translational plan, including creation of plans for pre-clinical and clinical development, translation strategy, and approach to future funding.

Who is this for?

If your technology has the potential to change patient outcomes, then this programme is for you. We are searching for novel and innovative therapeutic approaches to treat autoimmune diseases and chronic inflammation. Whether a new target or a new approach, we are looking to support you to bridge the gap through to pre-clinical development.

On this programme you will work directly with a cross-functional team covering pharmacology, DMPK, clinical, finance and entrepreneurship to expand your data package and evaluate your commercial proposition in the market.

As part of this pilot programme we are looking for two projects to support over a 4-6 month period.

Requirements

  • UK based academic 
  • All modalities are eligible
  • Developing a technology or approach that will treat an unmet need in an autoimmune, immune-mediated inflammatory disease or condition of chronic inflammation
  • Evidence from early efficacy data (in vitro or in vivo) or proof of the therapeutic principal via surrogate methods
  • Selection criteria
  • There must be a clear unmet need in the chosen indication
  • The approach must be differentiated from existing therapeutic (we are not looking for “me-too” approaches)

Key dates

Applications will be considered on a rolling basis, with a final deadline to apply of 17 February 2023.

What is this not?

This is not a grant, rather it is a research collaboration with the aim to explore approaches to develop life changing therapeutics for patients with autoimmune and chronic inflammatory diseases.

How to apply?

Please send a brief overview of your research or non-confidential deck to Jason Goldstein or Richard Kaschula at j.goldstein@ngbio.co.uk or r.kaschula@ngbio.co.uk.

Questions?

Should you have any questions, please reach out to Jason Goldstein at j.goldstein@ngbio.co.uk.

Who are we?

NG Bio is a therapeutic venture builder. Together with academic and scientific founders, we develop therapies that target autoimmune and chronic inflammatory diseases.

 

 

Back to top